Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;22(3):422-428.
doi: 10.1111/vco.12990. Epub 2024 Jun 18.

Use of Lomustine and Prednisolone as First-Line Treatment in Canine Multicentric Lymphoma

Chiara Catalucci  1 , Marco Luigi Bianchi  2 , Elisabetta Treggiari  3 , Marta Pieri  2 , Katja Ruess  4 , Paola Valenti  1
Affiliations

Use of Lomustine and Prednisolone as First-Line Treatment in Canine Multicentric Lymphoma

Chiara Catalucci et al. Vet Comp Oncol. 2024 Sep.

Abstract

Multiagent chemotherapy is considered the most effective treatment for canine high-grade lymphoma; however, due to cost and time requirements, single-agent protocols have also been described. The aim of our study was to evaluate the outcome and prognostic factors of dogs affected by multicentric lymphoma treated with lomustine and prednisolone as first-line treatment. Cases of medium-large-cell multicentric lymphoma treated with lomustine and prednisolone were included in the study. Response to therapy, time to progression (TTP), median disease-free interval (MDFI) and median survival time (MST) were retrospectively described. Thirty cases were included. Eleven (36.67%) were T cell, 11 (36.67%) were B cell and 8 (26.66%) had unknown immunophenotype. The overall response rate (RR) was 87%, with 15 patients achieving CR (50%) and 11 patients PR (37%). The median TTP, MDFI and MST were 42, 63 and 90 days, respectively. The only factor significantly associated with MDFI and MST was the stage. Dogs with multicentric lymphoma treated with lomustine and prednisolone have lower RR, TTP, MDFI and MST compared with dogs receiving multiagent protocols. Based on the short-lasting response, this study confirms that this protocol might have minimal utility beyond palliation.

Keywords: chemotherapy; dog; lomustine; lymphoma.

PubMed Disclaimer

References

    1. D. M. Vail and K. M. Young, “Canine Lymphoma and Lymphoid Leukemia,” in Withrow and MacEwen's Small Animal Clinical Oncology, 4th ed., eds. S. J. Withrow and D. M. Vail (St. Louis: Saunders Elsevier, 2007), 699–733.
    1. J. M. Dobson, L. B. Blackwood, E. F. Mcinnes, et al., “Prognostic Variables in Canine Multicentric Lymphosarcoma,” Journal of Small Animal Practice 42 (2001): 377–384.
    1. L. D. Garrett, D. H. Thamm, R. Chun, R. Dudley, and D. M. Vail, “Evaluation of a 6‐Month Chemotherapy Protocol With No Maintenance Therapy for Dogs With Lymphoma,” Journal of Veterinary Internal Medicine 16 (2002): 704–709.
    1. K. Sorenmo, B. Overley, E. Krick, T. Ferrara, A. LaBlanc, and F. Shofer, “Outcome and Toxicity Associated With a Dose‐Intensified, Maintenance‐Free CHOP‐Based Chemotherapy Protocol in Canine Lymphoma: 130 Cases,” Veterinary and Comparative Oncology 8, no. 3 (2010): 196–208.
    1. J. H. Burton, E. Garrett‐Mayer, and D. H. Thamm, “Evaluation of a 15‐Week CHOP Protocol for the Treatment of Canine Multicentric Lymphoma,” Veterinary and Comparative Oncology 11 (2013): 306–315.

LinkOut - more resources